Royal Bank Of Canada Issues Positive Forecast for Beam Therapeutics (NASDAQ:BEAM) Stock Price

Beam Therapeutics (NASDAQ:BEAM) had its price target lifted by Royal Bank Of Canada from $22.00 to $26.00 in a research note published on Wednesday morning, Marketbeat reports. The firm currently has a sector perform rating on the stock.

Other equities analysts have also recently issued research reports about the company. Wedbush lifted their target price on Beam Therapeutics from $57.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday. UBS Group began coverage on shares of Beam Therapeutics in a research report on Wednesday, January 7th. They set a “neutral” rating and a $28.00 price objective on the stock. Benchmark reiterated a “speculative buy” rating on shares of Beam Therapeutics in a research note on Monday, November 17th. Evercore began coverage on shares of Beam Therapeutics in a research note on Monday, November 24th. They set an “outperform” rating and a $35.00 target price for the company. Finally, Wall Street Zen downgraded shares of Beam Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.19.

Beam Therapeutics Trading Down 8.3%

NASDAQ BEAM opened at $29.61 on Wednesday. Beam Therapeutics has a 1 year low of $13.52 and a 1 year high of $36.44. The company has a market cap of $3.00 billion, a PE ratio of -29.32 and a beta of 2.12. The stock’s 50-day moving average price is $28.82 and its two-hundred day moving average price is $25.02.

Beam Therapeutics (NASDAQ:BEAM) last announced its earnings results on Tuesday, February 24th. The company reported $2.33 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $3.46. The company had revenue of $114.11 million for the quarter, compared to the consensus estimate of $13.22 million. Beam Therapeutics had a negative net margin of 57.24% and a negative return on equity of 32.06%. The company’s revenue was up 280.3% on a year-over-year basis. During the same period in the previous year, the business earned ($1.09) EPS. Research analysts forecast that Beam Therapeutics will post -4.57 EPS for the current fiscal year.

Insider Buying and Selling at Beam Therapeutics

In related news, insider Christine Bellon sold 18,629 shares of Beam Therapeutics stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $34.61, for a total value of $644,749.69. Following the completion of the sale, the insider owned 97,038 shares of the company’s stock, valued at approximately $3,358,485.18. The trade was a 16.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.50% of the company’s stock.

Institutional Trading of Beam Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Allworth Financial LP increased its holdings in shares of Beam Therapeutics by 7,080.0% during the 2nd quarter. Allworth Financial LP now owns 2,513 shares of the company’s stock valued at $43,000 after acquiring an additional 2,478 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Beam Therapeutics in the fourth quarter valued at approximately $47,000. Larson Financial Group LLC raised its position in shares of Beam Therapeutics by 4,370.5% in the third quarter. Larson Financial Group LLC now owns 1,967 shares of the company’s stock valued at $48,000 after purchasing an additional 1,923 shares during the period. Van ECK Associates Corp lifted its stake in shares of Beam Therapeutics by 48.7% in the third quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock worth $52,000 after buying an additional 707 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in shares of Beam Therapeutics during the 4th quarter worth $59,000. Institutional investors and hedge funds own 99.68% of the company’s stock.

Beam Therapeutics News Summary

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Beam reported a blowout Q4: $2.33 EPS vs. consensus of -$1.13 and revenue of $114.1M vs. ~$13M expected — results materially beat street estimates and show strong year‑over‑year revenue growth. Press Release / Results
• Positive Sentiment: Beam secured a $500M strategic financing facility with Sixth Street ($100M funded at close, up to $400M available) — long‑dated, non‑dilutive capital to support a potential launch (extends cash runway). Financing Announcement
• Positive Sentiment: Pfizer locked a global license for one of Beam’s gene‑editing candidates after exiting a gene therapy program — validates partnering interest and external commercialization potential. FierceBiotech Article
• Positive Sentiment: Wedbush raised its price target to $65 and kept an outperform rating — a bullish analyst call that signals upside from current levels. Wedbush / Coverage
• Neutral Sentiment: Beam announced a new liver‑targeted program for PKU and expects an IND for BEAM‑304 in 2026 — a constructive R&D development but early‑stage and not an immediate revenue driver. GenEngNews on PKU program
• Neutral Sentiment: Multiple earnings summaries and the full call transcript are available for deeper read — useful for investors assessing sustainability of revenue and margins. Earnings Call Summary
• Negative Sentiment: RBC raised its target to $26 but kept a “sector perform” rating — that target implies downside vs. current levels and may encourage some selling or limit upside momentum. The Fly / RBC Note
• Negative Sentiment: Despite strong fundamentals, short‑term price weakness appears driven by profit‑taking and mixed analyst views; coverage pieces asking “what’s going on” reflect near‑term uncertainty among traders. MSN Coverage

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.